While first-generation immune-oncology therapies for non-solid tumors, such as checkpoint inhibitors and CAR-T procedures represent a remarkable therapeutic advance, solid tumors remain harder to treat, primarily due to the complex and interconnected tumor microenvironment (TME).
Enlivex has discovered a proprietary macrophage-modulation pathway for solid tumors, which is activated through the engulfment of Allocetra™.
Allocetra™ is being developed as an adjunctive therapy for solid tumors, and is designed to significantly increase the efficacy of approved solid cancer therapeutic agents such as immune checkpoint inhibitors.
Clinical development for treatment of solid tumors:
The data from our extensive preclinical studies shows that the Allocetra cells, which have shown robust safety profile sepsis and COVID-19 patients, have reprogrammed macrophage populations in the tumor microenvironment and surrounding tissues, resulting in a major increase in duration of survival complete remission rates or preclinical subjects.
The Company is scheduled to initiate several solid tumor clinical trials during 2022.